2021
Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System
John BV, Schwartz K, Scheinberg AR, Dahman B, Spector S, Deng Y, Goldberg D, Martin P, Taddei TH, Kaplan DE. Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System. Transplantation 2021, 106: 72-84. PMID: 33587434, PMCID: PMC8239056, DOI: 10.1097/tp.0000000000003615.Peer-Reviewed Original ResearchMeSH KeywordsHumansLiver TransplantationProportional Hazards ModelsReferral and ConsultationRetrospective StudiesUnited StatesWaiting ListsConceptsLiver transplantationTransplant centersPretransplant mortalityMultivariable Cox hazard modelTransplant evaluation processSuccessful liver transplantationMulticenter retrospective studyEvaluation of patientsVA health systemDays of referralCox hazard modelPosttransplant deathTransplant evaluationPosttransplant mortalityHigher MELDMulticenter analysisRetrospective studyList dropoutReduced mortalityHazards modelPatientsTransplantationReferralHealth systemMortalityCoronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients
John BV, Deng Y, Khakoo NS, Taddei TH, Kaplan DE, Dahman B. Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients. Gastroenterology 2021, 162: 645-647.e2. PMID: 34758352, PMCID: PMC8572555, DOI: 10.1053/j.gastro.2021.11.001.Peer-Reviewed Original ResearchConceptsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccinationCoronavirus 2 infectionLiver transplant recipientsTransplant recipientsVaccinationInfectionRecipientsMale Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis
John BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei T, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver‐Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology 2021, 74: 879-891. PMID: 33636012, DOI: 10.1002/hep.31776.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisLiver-related deathHepatocellular carcinomaBiliary cholangitisMale sexTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityHigher unadjusted ratesRisk of deathVeterans Health AdministrationProportional hazards modelAssociation of sexImpact of sexPBC cirrhosisMale patientsUnadjusted ratesWorse outcomesTotal bilirubinCirrhosisLarge cohortHigh riskHazards modelTransplantationFactors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease
Kanwal F, Hernaez R, Liu Y, Taylor TJ, Rana A, Kramer JR, Naik AD, Smith D, Taddei T, Asch SM. Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine 2021, 181: 949-959. PMID: 34028505, PMCID: PMC8145153, DOI: 10.1001/jamainternmed.2021.2051.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseAdvanced liver diseaseLiver diseaseLiver transplantationCohort studyMedical recordsOrgan transplantsVeterans Affairs Health Care SystemLower ratesRetrospective cohort studyWait-listed patientsAfrican American patientsComprehensive electronic medical recordsElectronic medical recordsHealth care systemReferral stepsLiver allograftsLiver transplantAdult patientsAlcohol etiologyLow annual incomePatient ageCurative therapyLiver cirrhosisSodium scoreUrsodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis
John BV, Khakoo NS, Schwartz KB, Aitchenson G, Levy C, Dahman B, Deng Y, Goldberg DS, Martin P, Kaplan DE, Taddei TH. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. The American Journal Of Gastroenterology 2021, 116: 1913-1923. PMID: 33989225, PMCID: PMC8410631, DOI: 10.14309/ajg.0000000000001280.Peer-Reviewed Original ResearchConceptsLiver-related deathPrimary biliary cholangitisUDCA responseHepatic decompensationHepatocellular carcinomaUrsodeoxycholic acidUDCA respondersPortal hypertensionPartial respondersBiliary cholangitisTime-updated Cox proportional hazards modelsCox proportional hazards modelUrsodeoxycholic acid responseLiver-related mortalityRetrospective cohort studyProportional hazards modelPBC cirrhosisCompensated cirrhosisCohort studyMale patientsClinical benefitUnadjusted ratesCirrhosisReduced mortalityDecompensationFrailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries
Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries. Liver Transplantation 2021, 27: 699-710. PMID: 33226691, PMCID: PMC8517916, DOI: 10.1002/lt.25953.Peer-Reviewed Original ResearchMeSH KeywordsChildEnd Stage Liver DiseaseFrailtyHumansLiver CirrhosisLiver TransplantationPrognosisRetrospective StudiesRisk FactorsSeverity of Illness IndexConceptsMayo risk scoreHospital Frailty Risk ScorePostoperative mortalityPatient frailtyRisk scoreMELD-NaMajor surgeryLiver diseaseRisk factorsEnd-stage liver diseaseFrailty Risk ScorePreoperative frailty assessmentRetrospective cohort studySurgical risk scoresMajority of patientsCox regression modelPoor postoperative survivalRisk prediction modelAdditional important predictorChild-TurcotteFrailty assessmentFrailty scorePostoperative survivalCohort studyPostoperative riskAdvance Care Planning: A Convincing Argument to Make It Part of Liver Transplant Evaluation
Verma M, Taddei T, Volk M, Navarro V. Advance Care Planning: A Convincing Argument to Make It Part of Liver Transplant Evaluation. Liver Transplantation 2021, 27: 461-462. PMID: 32978855, DOI: 10.1002/lt.25901.Peer-Reviewed Original ResearchThe Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis Cohort
Mahmud N, Asrani SK, Kaplan DE, Ogola GO, Taddei TH, Kamath PS, Serper M. The Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis Cohort. Liver Transplantation 2021, 27: 177-189. PMID: 33025731, PMCID: PMC7880877, DOI: 10.1002/lt.25913.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseHospital mortalityLactate clearanceCirrhosis hospitalizationsMELD-NaLiver diseaseDay 1Predictive roleRetrospective cohort studyIn-Hospital MortalityRisk-stratify patientsVeterans Health AdministrationCirrhosis cohortMELD categoriesGastrointestinal bleedingCohort studyClinical dataLimited cohortStratified analysisLactate levelsHospitalizationHealth AdministrationMELDClinical toolMortalityPatient Frailty Is Independently Associated With the Risk of Hospitalization for Acute‐on‐Chronic Liver Failure
Shah S, Goldberg DS, Kaplan DE, Sundaram V, Taddei TH, Mahmud N. Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acute‐on‐Chronic Liver Failure. Liver Transplantation 2021, 27: 16-26. PMID: 32946660, PMCID: PMC8249075, DOI: 10.1002/lt.25896.Peer-Reviewed Original ResearchMeSH KeywordsAcute-On-Chronic Liver FailureFrailtyHospitalizationHumansLiver CirrhosisLiver TransplantationPrognosisRetrospective StudiesConceptsChronic liver failureFrailty scoreACLF mortalityPatient frailtyLiver failureLongterm survivalPoorer longterm survivalImpact of frailtyRisk of hospitalizationTime of hospitalizationWait-list mortalityACLF developmentCirrhosis hospitalizationsFrail outpatientsTransplant evaluationFirst hospitalizationPosttransplant outcomesTransplant candidatesCox analysisRetrospective studyCox regressionUS veteransRisk factorsHospitalizationAdjusted model
2020
Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Re V. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 71-78. PMID: 31575557, PMCID: PMC6980754, DOI: 10.1158/1055-9965.epi-19-0503.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesCarcinoma, HepatocellularFemaleHepatectomyHIV InfectionsHospitals, VeteransHumansImmunologic SurveillanceKaplan-Meier EstimateLiverLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesConceptsBarcelona Clinic Liver Cancer stageHIV statusHepatocellular carcinomaUninfected patientsHIV infectionTumor characteristicsUninfected personsPathology reportsVeterans Aging Cohort StudyLiver tissue samplingCohort of HIVMultivariable Cox regressionAdvanced hepatic fibrosisAging Cohort StudyLiver Cancer stageRisk of deathBackground hepatic parenchymaCohort studyHazard ratioLymphovascular invasionBCLC stageImproved survivalCox regressionHistologic featuresHepatic fibrosisSurvival Benefit of Liver Transplantation for Hepatocellular Carcinoma.
Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2020, 104: 104-112. PMID: 31283688, PMCID: PMC6928443, DOI: 10.1097/tp.0000000000002816.Peer-Reviewed Original ResearchConceptsIncremental survival benefitLiver transplantSurvival benefitHepatocellular carcinomaEnd-stage liver disease (MELD) scoreOverall long-term survivalIntermediate-stage hepatocellular carcinomaLiver Disease scoreRetrospective cohort studyStage hepatocellular carcinomaHazard of deathVeterans Health AdministrationImmortal time biasLong-term survivalUnderwent resectionLiver transplantationAnalytic cohortCohort studyCurative optionMultivariable modelHCC diagnosisDisease scoreResectionPatientsHealth Administration
2019
Macrotrabecular Hepatocellular Carcinoma
Jeon Y, Benedict M, Taddei T, Jain D, Zhang X. Macrotrabecular Hepatocellular Carcinoma. The American Journal Of Surgical Pathology 2019, 43: 943-948. PMID: 31135484, DOI: 10.1097/pas.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlpha-FetoproteinsCarcinoma, HepatocellularDisease ProgressionFemaleHepatectomyHepatitis BHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingProgression-Free SurvivalRetrospective StudiesRisk FactorsTime FactorsTumor BurdenConceptsHepatocellular carcinomaHCC subtypesHigh alpha-fetoprotein levelsWorse recurrence-free survivalDistinct HCC subtypeHepatitis C infectionRecurrence-free survivalAlpha-fetoprotein levelsAnaplastic tumor cellsHigh histologic gradePoor overall survivalConventional hepatocellular carcinomaHigh recurrence rateHigher AJCC stageDetailed pathologic evaluationMacrotrabecular patternC infectionPrimary resectionHepatitis BOverall survivalPathologic evaluationAJCC stageClinicopathologic featuresHistologic subtypeRecurrence ratePre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortality
Mahmud N, John B, Taddei T, Goldberg DS. Pre‐transplant alpha‐fetoprotein is associated with post‐transplant hepatocellular carcinoma recurrence mortality. Clinical Transplantation 2019, 33: e13634. PMID: 31177570, PMCID: PMC6635076, DOI: 10.1111/ctr.13634.Peer-Reviewed Original ResearchConceptsHCC recurrenceLiver transplantationAlpha-fetoproteinHepatocellular carcinomaLiver diseaseHepatitis C liver diseaseEnd-stage liver diseaseC liver diseasePre-transplant modelRetrospective cohort studyOrgan Sharing databaseAdult transplant recipientsCox regression analysisTransplant recipientsCohort studySharing databaseMedian timeAFP levelsCox regressionPatient survivalUnited NetworkPoor survivalHigh riskRecurrencePatients
2018
Palliative care in decompensated cirrhosis: A review
Langberg KM, Kapo JM, Taddei TH. Palliative care in decompensated cirrhosis: A review. Liver International 2018, 38: 768-775. PMID: 29112338, DOI: 10.1111/liv.13620.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsHospital CostsHumansLiver CirrhosisLiver TransplantationPalliative CarePatient Reported Outcome MeasuresQuality of LifeReferral and ConsultationConceptsPalliative carePatient populationProspective randomized control trialIncidence of cirrhosisPalliative care consultationAdvanced care planningPatient-reported outcomesSmall observational studiesPotential treatment optionCost of careRandomized control trialQuality of lifeLiver transplantSymptom controlICU utilizationLiver diseaseCare consultationsTreatment optionsPatient satisfactionHospital costsObservational studyCirrhosisCare planningControl trialOnly cure
2016
Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis
Langberg KM, Taddei TH. Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis. Hepatology 2016, 64: 1014-1016. PMID: 27388118, DOI: 10.1002/hep.28717.Commentaries, Editorials and LettersRecalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis
Kaplan DE, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Taddei T, for the VOCAL Study Group. Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. Digestive Diseases And Sciences 2016, 61: 3309-3320. PMID: 27405990, PMCID: PMC5067291, DOI: 10.1007/s10620-016-4239-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBilirubinCreatinineDisease ProgressionEnd Stage Liver DiseaseEvidence-Based MedicineFemaleHumansInternational Normalized RatioLiver CirrhosisLiver TransplantationMaleMiddle AgedOdds RatioPrognosisProportional Hazards ModelsRetrospective StudiesSerum AlbuminSeverity of Illness IndexUnited StatesVeteransConceptsTransplant-free survivalHarrell's C-statisticC-statisticPugh scoreChild-TurcotteCTP scoreHighest Harrell's C-statisticsCox proportional hazards modelEvidence-based cutpointProportional hazards modelLong-term survivalEtiology subgroupsSerum creatinineVeteran patientsLaboratory variablesRisk ratioTotal bilirubinHazards modelCirrhosisPatientsLower cutpointsDisease etiologySurvivalCutpointsScores
2011
Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience
Cimsit B, Schilsky M, Moini M, Cartiera K, Arvelakis A, Kulkarni S, Formica R, Caldwell C, Taddei T, Asch W, Emre S. Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience. Transplantation Proceedings 2011, 43: 901-904. PMID: 21486624, DOI: 10.1016/j.transproceed.2011.02.033.Peer-Reviewed Original ResearchConceptsLiver-kidney transplantationHigh MELD scoreKidney transplantationMELD scoreKidney diseaseEnd-stage liver disease (MELD) scoreCombined liver-kidney transplantationGraft/patient survivalLow glomerular filtration rateOrgan allocation algorithmsPrimary biliary sclerosisRecurrence of HCVSevere HCV recurrenceTransplantation of patientsLiver Disease scoreSerum creatinine levelsRenal allograft rejectionSingle-center experienceGlomerular filtration rateHepatitis C virusPolycystic kidney diseaseBiliary sclerosisHCV recurrenceIschemic hepatitisOLT patientsSuccessful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipients
2004
Impact of body mass index on graft failure and overall survival following liver transplant*
Rustgi VK, Marino G, Rustgi S, Halpern MT, Johnson LB, Tolleris C, Taddei TH. Impact of body mass index on graft failure and overall survival following liver transplant*. Clinical Transplantation 2004, 18: 634-637. PMID: 15516235, DOI: 10.1111/j.1399-0012.2004.00141.x.Peer-Reviewed Original ResearchMeSH KeywordsBody Mass IndexGraft SurvivalHumansLiver TransplantationPostoperative ComplicationsRenal InsufficiencyRisk FactorsConceptsElevated body mass indexBody mass indexLower body mass indexLikelihood of deathMass indexLiver transplantLiver transplantationGraft failureImpact of BMIHigher body mass indexGraft failure rateNumber of comorbiditiesOrgan Sharing databaseOverall survival rateProportional hazards regressionRisk of deathOverall survivalSharing databaseHazards regressionUnited NetworkRisk factorsBMI valuesPatientsSurvival rateDecreased likelihood